Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

被引：6

作者：

Poizot-Martin, I ^{[1
,2
]}

Obry-Roguet, V ^{[2
]}

Duvivier, C. ^{[3
,4
,5
,6
]}

Lions, C. ^{[2
]}

Huleux, T. ^{[7
]}

Jacomet, C. ^{[8
]}

Ferry, T. ^{[9
]}

Cheret, A. ^{[10
,11
]}

Allavena, C. ^{[12
]}

Bani-Sadr, F. ^{[13
]}

Palich, R. ^{[14
,15
]}

Cabie, A. ^{[16
,17
,18
]}

Fresard, A. ^{[19
]}

Pugliese, P. ^{[20
]}

Delobel, P. ^{[21
]}

Lamaury, I ^{[22
]}

Hustache-Mathieu, L. ^{[23
]}

Bregigeon, S. ^{[2
]}

Makinson, A. ^{[24
]}

Rey, D. ^{[25
]}

机构：

[1] Aix Marseille Univ, Sci Econ & Sociales Sante & Traitement Informat M, APHM St Marguerite, Serv Immunohematol Clin,INSERM,IRD,SESSTIM, Marseille, France

[2] Aix Marseille Univ, Serv Immunohematol Clin, APHM St Marguerite, Marseille, France

[3] Hop Necker Enfants Malad, AP HP, Ctr Infectiol Necker Pasteur, Serv Malad Infect & Trop, Paris, France

[4] IHU Imagine, Paris, France

[5] Univ Paris, Inst Cochin, RIL Team Retrovirus Infect & Latency, CNRS 8104,INSERM U1016, Paris, France

[6] Inst Pasteur, Ctr Med Inst Pasteur, Paris, France

[7] Ctr Hosp G DRON, Serv Univ Malad Infect & Voyageur, Tourcoing, France

[8] CHU Clermont Ferrand, Dept Malad Infect & Trop, Clermont Ferrand, France

[9] Univ Claude Bernard Lyon 1, Serv Malad Infect, Hosp Civils Lyon, Villeurbanne, France

[10] Univ Paris 05, EA7327, Sorbonne Paris Cite, Paris, France

[11] Hop Bicetre, AP HP, Serv Med Interne, Immunol Clin, Le Kremlin Bicetre, France

[12] CHU Hotel Dieu, Serv Malad Infect & Trop, Nantes, France

[13] Ctr Hosp Univ, Dept Med Interne, Hop Robert Debro, Malad Infect & Immunol Clin, Reims, France

[14] GHPS Pitie Salpetriere, AP HP, Serv Malad Infect & Trop, Paris, France

[15] UPMC Univ Paris 6, Sorbonne Univ, UMR 1136, INSERM,IPLESP, Paris, France

[16] CHU Martinique, Serv Malad Infect & Trop, Fort De France, Martinique, France

[17] Univ Antilles, EA Malad Infect & Trop Caraibe 4537, Pointe A Pitre, Guadeloupe, France

[18] Ctr Hosp Andree Rosemon, Ctr dInvest Clin Antilles Guyane, INSERM CIC1424, Cayenne, France

[19] CHU St Etienne, Dept Malad Infect & Trop, St Etienne, France

[20] Univ Cote dAzur, CHU Nice, Nice, France

[21] Univ Toulouse III Paul Sabatier, Serv Malad Infect & Trop, CHU Toulouse, INSERM,UMR1043, Toulouse, France

[22] Dept Infectiol Dermatol & Immunol Clin, Pointe A Pitre, Guadeloupe, France

[23] CHRU Besancon Hop Jean Minjoz, Serv Malad Infect & Trop, Besancon, France

[24] CHU Montpellier, Dept Malad Infect & Trop, INSERM U1175,IRD UMI 233, Montpellier, France

[25] Hop Univ, Ctr Soins Infect VIH, Le Trait Union, Strasbourg, France

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2020年 / 34卷 / 05期

关键词：

PROTEASE INHIBITORS; INFECTED PATIENT; HUMAN-HERPESVIRUS-8; EPIDEMIOLOGY; CONTEXT; WELL;

D O I：

10.1111/jdv.16204

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background Although antiretroviral therapy (ART) has reduced the risk of Kaposi sarcoma (KS), KS cases still occur in HIV-infected people. Objective To describe all KS cases observed between 2010 and 2015 in a country with high ART coverage. Methods Retrospective study using longitudinal data from 44 642 patients in the French Dat'AIDS multicenter cohort. Patients' characteristics were described at KS diagnosis according to ART exposure and to HIV-plasma viral load (HIV-pVL) (<= 50 or >50) copies/mL. Results Among the 209 KS cases diagnosed during the study period, 33.2% occurred in ART naive patients, 17.3% in ART-experienced patients and 49.5% in patients on ART, of whom 23% for more than 6 months. Among these patients, 24 (11.5%) had HIV-pVL <= 50 cp/mL, and 16 (66%) were treated with a boosted-PI-based regimen. The distribution of KS localization did not differ by ART status nor by year of diagnosis. Limitations Data on human herpesvirus 8, treatment modalities for KS and response rate were not collected. Conclusion Half of KS cases observed in the study period occurred in patients not on ART, reflecting the persistence of late HIV diagnosis. Factors associated with KS in patients on ART with HIV-pVL <= 50 cp/mL remain to be explored.

引用

页码：1065 / 1073

页数：9

共 33 条

[1]

[Anonymous], GUID US ANT AG AD AD

[2] Human Immunodeficiency Virus Type 1 Tat Accelerates Kaposi Sarcoma-Associated Herpesvirus Kaposin A-Mediated Tumorigenesis of Transformed Fibroblasts In Vitro as well as in Nude and Immunocompetent Mice [J].